DiaMedica Therapeutics Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
DiaMedica Therapeutics Inc. (DMAC) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $100.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2025-08-12
- DiaMedica Therapeutics Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2024-06-30 was $100.00K, a 92.86% decline year-over-year.
- DiaMedica Therapeutics Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2023-09-30 was $4.00K.
- DiaMedica Therapeutics Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2023-06-30 was $1.40M.
- DiaMedica Therapeutics Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2021-09-30 was $100.00K, a 94.44% decline year-over-year.
- DiaMedica Therapeutics Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2024 was $100.00K, a 92.86% decline from fiscal 2023.
- DiaMedica Therapeutics Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2023 was $1.40M, a 827.15% increase from fiscal 2022.
- DiaMedica Therapeutics Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2022 was $151.00K, a 0.00% change from fiscal 2021.
- DiaMedica Therapeutics Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2021 was $151.00K.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|---|
| 2024-12-31 | $100.00K 10-K · filed 2025-03-17 | ||
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-12 | ||
| 2023-12-31 | $1.40M 10-K · filed 2025-03-17 | ||
| 2023-09-30 | $4.00K 10-Q · filed 2024-11-13 | $1.40M derived: sum of 2 quarters · filed 2024-11-13 | |
| 2023-06-30 | $1.40M 10-Q · filed 2024-11-13 | ||
| 2022-12-31 | $151.00K 10-K · filed 2023-03-28 | ||
| 2021-12-31 | $151.00K 10-K · filed 2022-03-14 | ||
| 2021-09-30 | $100.00K 10-Q · filed 2022-11-09 | ||
| 2020-09-30 | $1.80M 10-Q · filed 2021-11-10 | ||
| 2017-12-31 | $292.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |